Pregnancy Outcomes for Cardiovascular Disease
(nuMoM2b-HHS2 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to understand how certain problems during pregnancy, known as adverse pregnancy outcomes (APOs), might affect women's heart health later in life. Researchers are tracking a group of women from a previous study to observe changes in their heart health over time. Women who participated in the earlier study and are at least three months postpartum from any pregnancy may be suitable candidates for this trial. The goal is to improve doctors' ability to predict, prevent, and treat heart disease in women. As an unphased trial, this study offers a unique opportunity to contribute to groundbreaking research that could enhance heart health care for women.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the study coordinators or your doctor.
Why are researchers excited about this trial?
Researchers are excited about the continuation of the nuMoM2b Heart Health Study because it focuses on understanding long-term heart health in women who have had a recent pregnancy. Unlike treatments that address heart conditions with medications or surgeries, this study aims to provide insights into how pregnancy affects heart health over time. By continuing to follow participants, researchers hope to uncover patterns and predictors of heart disease, potentially leading to better preventive measures and early interventions for women after childbirth.
Who Is on the Research Team?
Rebecca McNeil, PhD
Principal Investigator
RTI International
George Saade, MD
Principal Investigator
Old Dominion University
Phillip Greenland, MD
Principal Investigator
Northwestern University
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Data Collection
Prospective collection of longitudinal data on CVD risk factors and early clinical manifestations of CVD
In-Person Visit
Collection of blood pressure, pulse rate, weight, height, body measurements, fasting blood draw, and urine specimen
Follow-up
Participants are monitored for CVD events, conditions, and diagnostic and therapeutic procedures
What Are the Treatments Tested in This Trial?
Interventions
- Continued Follow-up
Find a Clinic Near You
Who Is Running the Clinical Trial?
RTI International
Lead Sponsor
University of Michigan
Collaborator
West Virginia University
Collaborator
Eastern Virginia Medical School
Collaborator
Old Dominion University
Collaborator
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
The University of Texas Medical Branch, Galveston
Collaborator
Northwestern University
Collaborator
Ohio State University
Collaborator
Cedars-Sinai Medical Center
Collaborator